ImmunityBio Clinical Trial for Lymphoma Drug Follows $505M Convertible Note Change

ImmunityBio is conducting a clinical trial for a lymphoma drug, following a significant $505 million convertible note change.

19 Feb, 00:38 — 19 Feb, 00:38